Episode Details

Kathleen Goin, COO of Palvella Therapeutics, sold 4,302 shares after exercising the same number of options, totaling $508,000. This sale, part of a recent pattern, left her with no direct shares, but she still holds options. Palvella, a biotech firm targeting rare skin diseases, saw its stock surge 340% in a year, despite a net loss. Investors watch insider moves, but Goins pattern is common for option management.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/471e16a9cc919956